Microclot testing is still largely a research tool, not a routine clinical lab order. The most established method uses fluorescence microscopy with a dye called thioflavin T, which lights up the abnormal amyloid-like fibrin structures that define these clots. Several newer approaches, including imaging flow cytometry and thromboelastography, are expanding the toolkit, but none has yet been validated for widespread diagnostic use. For anyone dealing with Long COVID, ME/CFS, or other post-infectious conditions where microclots are suspected, understanding what these tests actually measure and where they stand in terms of availability matters a great deal.
What Microclots Actually Are
Microclots are not simply tiny versions of the blood clots that cause heart attacks or strokes. They are dense, tangled deposits of fibrin, the protein that normally forms a scaffold when blood clots. In microclots, fibrin folds into an unusual structure that researchers describe as “amyloid,” the same type of misfolded protein arrangement seen in diseases like Alzheimer’s. This amyloid form of fibrin resists the body’s normal clot-dissolving machinery, which is why these deposits can persist in the bloodstream for weeks or months rather than being cleared in the usual timeframe.1PubMed Central. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
Research on Long COVID patients has shown that their platelet-poor plasma contains large anomalous deposits that are resistant to fibrinolysis even after being treated with digestive enzymes, while plasma from healthy controls and people with type 2 diabetes does not show the same resistance.2PubMed Central. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin This persistence is the core clinical concern: if the body cannot break these clots down, they may block small blood vessels, reduce oxygen delivery to tissues, and contribute to symptoms like fatigue, brain fog, and exercise intolerance.
How Microclots Form
The triggers behind microclot formation are still being mapped out, but two pathways have drawn the most attention. The first involves the SARS-CoV-2 spike protein itself. When exposed to neutrophil elastase, an enzyme the immune system releases heavily at sites of inflammation, the spike protein gets cleaved in ways that expose amyloid-prone segments. One particularly amyloid-forming peptide fragment has been identified, and the fact that neutrophil elastase is overexpressed during viral infection provides a plausible route from infection to abnormal clotting.3Journal of the American Chemical Society. Amyloidogenesis of SARS-CoV-2 Spike Protein
The second pathway is even more striking for its sensitivity. Researchers found that bacterial lipopolysaccharide, a molecule shed by bacteria in the gut and elsewhere, can trigger amyloid fibrin clotting at extraordinarily low concentrations: roughly one molecule of lipopolysaccharide for every hundred million fibrinogen molecules.4Biochemical Journal. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications This finding suggests that even low-grade bacterial translocation from a compromised gut lining could be enough to keep microclots forming long after an acute infection has cleared.
Fluorescence Microscopy with Thioflavin T
The method that first brought microclots to wider scientific attention involves staining platelet-poor plasma with thioflavin T, a fluorescent dye that binds specifically to amyloid structures. Under a fluorescence microscope, normal plasma shows little or no fluorescent signal, while plasma loaded with amyloid fibrin microclots glows brightly. Researchers can then photograph the sample and measure the total fluorescent area as a proxy for microclot burden.5bioRxiv. Automated microscopic measurement of fibrinaloid microclots and their degradation by nattokinase, the main natto protease
This approach has a few practical strengths. Thioflavin T is cheap, widely available, and the staining protocol is straightforward enough that any lab with a fluorescence microscope can run it. It was also the method used in studies that first quantified the difference between Long COVID and healthy plasma, making it the reference standard that newer methods are benchmarked against. The downside is throughput: examining slides under a microscope and measuring fluorescent areas manually is slow, and human scoring introduces variability between labs and operators. Automated image analysis is in development to address this, but standardized protocols have not yet been agreed upon across research groups.
Imaging Flow Cytometry
To speed things up without losing the visual information that microscopy provides, researchers have turned to imaging flow cytometry. A conventional flow cytometer pushes particles through a laser beam one at a time and records scattered light, which tells you something about size and granularity but nothing about shape or internal structure. Imaging flow cytometry adds a camera, capturing an actual picture of each particle as it passes through the beam. This combination lets researchers process thousands of events per second while still being able to visually confirm whether a detected particle is genuinely an amyloid microclot or just debris.6PubMed Central. Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model
Studies using this method have found that Long COVID plasma contains a significantly greater concentration and size of microclots compared to healthy controls. The imaging component is key because it eliminates the kind of false positives that plague conventional flow cytometry, where a blob of debris or a platelet aggregate can register as a positive event. By actually seeing the particle, researchers can gate their analysis more accurately.7Heliyon. High-throughput detection of amyloid fibrin(ogen) microclots in plasma using imaging flow cytometry in Long COVID patients
The drawback is equipment cost. The instruments used in published studies, such as the Amnis FlowSight, are specialized and expensive, found mostly in well-funded research hospitals. This makes imaging flow cytometry an excellent research tool but an unlikely candidate for community labs or point-of-care testing anytime soon.
Thromboelastography
Thromboelastography, usually abbreviated TEG, takes a different approach. Instead of looking directly at microclots, it measures how blood or plasma clots and dissolves in real time, generating a profile of clotting speed, clot strength, and how readily the clot breaks down. In Long COVID patients, TEG profiles consistently show a hypercoagulable state: clots form faster than normal, reach greater strength, and resist dissolution.8medRxiv. Persistent Hypercoagulability and Further Characterization of Microclot Complexes in Long COVID
Specifically, studies report increased clot strength (measured by the maximum amplitude parameter) and reduced fibrinolysis at 30 minutes (a parameter called LY30), both of which point to a persistent state where clots form too easily and dissolve too slowly.9Blood Coagulation & Fibrinolysis. Dynamic microclot profiling: thromboelastography advances precision management in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome TEG has a practical advantage over microscopy: the machines are already present in many hospitals, particularly in surgical units and trauma centers where real-time clotting assessment guides transfusion decisions. This existing infrastructure means TEG could be repurposed for microclot-related investigations without buying new equipment.
That said, TEG does not directly detect or visualize microclots. It tells you the blood is clotting abnormally, but it cannot confirm whether that abnormality is specifically due to amyloid fibrin deposits, elevated clotting factors, platelet dysfunction, or some combination. Researchers have proposed combining TEG with microclot microscopy and platelet mapping for a more complete picture.10PubMed Central. TEG®, Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy
Proteomics of Trapped Molecules
One of the more revealing findings about microclots is that they are not just fibrin. When researchers dissolve them and analyze the contents, a range of inflammatory and clotting-related molecules tumble out. Proteomic analysis of microclots from Long COVID patients showed reduced levels of plasma kallikrein (part of the system that activates clot breakdown), elevated platelet factor 4 and von Willebrand factor (both associated with platelet activation and clot formation), and a marginal increase in alpha-2 antiplasmin, a protein that directly inhibits the enzyme responsible for dissolving clots.11PubMed Central. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system
This molecular profiling goes beyond simply detecting whether microclots are present. It offers clues about why they persist, since a buildup of antiplasmin and a deficit of clot-dissolving enzymes could create a self-reinforcing cycle. It also opens the door to distinguishing microclots driven by different underlying mechanisms, which may eventually matter for treatment selection. The limitation is that mass spectrometry-based proteomics is expensive, requires specialized facilities, and takes days to return results. It is a research discovery tool, not something you could run as a bedside assay.
Emerging Technologies
Several newer detection approaches are at earlier stages of development but worth tracking. Digital holo-tomographic microscopy creates three-dimensional maps of clot structures without needing any staining or labeling. When combined with Raman spectroscopy, which identifies molecules based on how they scatter laser light, researchers have been able to distinguish COVID-19 blood clot fragments from healthy ones based on their chemical signatures. Specifically, a fibrin-associated spectral peak at 976 cm⁻¹ appeared in COVID-19 clot samples but not in healthy ones.12PubMed Central. 3D Holo-tomographic Mapping of COVID-19 Microclots in Blood to Assess Disease Severity This kind of label-free, structural analysis could eventually allow microclot detection from a simple blood drop without the need for fluorescent dyes or sample preparation.
Optical biosensors designed for decentralized testing represent another frontier. These devices aim to bring coagulation monitoring out of hospital labs and into clinics or even homes, leveraging rapid optical detection to assess clotting behavior in real time.13PubMed Central. Optical Biosensors for Blood Coagulation Monitoring: Advantages, Limitations, and Translational Potential None has been specifically validated for microclot detection yet, but the engineering trajectory is clear: smaller, faster, cheaper devices that could make some form of clot profiling accessible outside of research centers.
On the laboratory modeling side, researchers have also developed bioprinted micro-clots to study how endothelial cells (the cells lining blood vessels) dissolve clots. These tiny printed fibrin constructs allow real-time tracking of clot breakdown under the microscope, providing a way to measure fibrinolytic capacity at a cellular level.14PubMed. Bioprinted Micro-Clots for Kinetic Analysis of Endothelial Cell-Mediated Fibrinolysis While this is currently a research assay rather than a diagnostic, it could eventually help clinicians understand whether a particular patient’s blood vessel lining is properly clearing clots.
Why Sample Handling Matters So Much
One of the biggest unresolved challenges in microclot testing is not the detection method itself but what happens to the blood sample before it reaches the instrument. Plasma samples drawn into citrate anticoagulant are sensitive to a range of handling variables: the temperature during transport and storage, whether the sample stays at room temperature or gets refrigerated or frozen, how hard and how long the sample is centrifuged, and even whether automated processing lines are used.15PubMed. Quality standards for sample processing, transportation, and storage in hemostasis testing
For standard clotting tests like PT and aPTT, the effects of these variables are well characterized and protocols are tightly controlled. For microclot assays, this standardization work is still in its early stages. A sample that sits too long at the wrong temperature could either generate artifacts (microclots forming in the tube after the draw) or lose real microclots (if they adhere to the tube walls or break apart). Until pre-analytical protocols are locked down across laboratories, results from different facilities may not be directly comparable. This is a mundane but critical bottleneck for moving microclot testing from research curiosity to reliable diagnostic.
Microclots Beyond Long COVID
Although Long COVID drove the initial wave of microclot research, these structures appear in other conditions too. Fluorescence microscopy has detected amyloid fibrin microclots across a range of chronic inflammatory diseases.16PubMed Central. A Perspective on How Fibrinaloid Microclots and Platelet Pathology May be Applied in Clinical Investigations The most detailed comparison so far is with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a condition that shares many symptoms with Long COVID. In ME/CFS patients, the area of plasma images containing microclots was commonly more than tenfold greater than in healthy controls, though the microclot burden was not as high as in Long COVID plasma.17PubMed Central. The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
This overlap has implications for testing. If microclots are a shared feature of post-viral and chronic inflammatory illnesses rather than unique to COVID-19, then a positive microclot test cannot by itself tell you the underlying cause. But it could serve as a biomarker for a specific type of vascular and clotting dysfunction that cuts across diagnostic categories, one that might respond to similar treatments regardless of the original trigger.
Using Microclot Tests to Track Treatment
Beyond initial diagnosis, microclot testing is starting to be used to monitor whether treatments are working. In case reports of patients receiving anticoagulant and antiplatelet therapy for Long COVID, serial microclot microscopy has been used alongside functional assessments and symptom tracking to gauge response over time.18Preprints. Microclots in Post‑COVID Condition: Clinical and Biomarker Response to Triple Antithrombotic Therapy. A Case Report If the fluorescent area shrinks after a course of treatment, that provides visual, semi-quantitative evidence that the intervention is reducing the clot burden.
The appeal is intuitive: instead of relying solely on whether a patient feels better (which is subjective and fluctuates), you have a physical measurement that can be photographed and compared over time. Researchers have proposed combining microclot imaging with proteomics, cytokine panels, and flow cytometry to build out a more comprehensive profile that could guide personalized treatment decisions.16PubMed Central. A Perspective on How Fibrinaloid Microclots and Platelet Pathology May be Applied in Clinical Investigations This is still aspirational; the monitoring framework exists in research settings but has not been incorporated into clinical guidelines.
What You Can Actually Get Tested Right Now
If you are a patient looking to have your blood tested for microclots today, the honest picture is limited. Most standard hospital labs do not offer thioflavin T microclot staining or imaging flow cytometry as orderable tests. TEG is available in many hospitals but is typically reserved for surgical or critical-care contexts, and most clinicians would not know how to interpret the results specifically in the context of microclot pathology.
A handful of research-oriented clinics and private laboratories in Europe and South Africa have offered microclot testing on a fee-for-service basis, usually involving fluorescence microscopy of platelet-poor plasma. The quality and reproducibility of these tests varies, and none operates under a universally accepted validation framework. If you do pursue testing, the questions worth asking are: what specific method is being used, whether the lab follows a standardized protocol for sample handling and staining, and how the results are quantified (visual scoring, automated image analysis, or something else).
Standard coagulation panels ordered through a regular doctor, things like D-dimer, fibrinogen levels, and basic clotting times, can sometimes hint at abnormal clotting activity but will miss amyloid microclots entirely. A normal D-dimer does not rule out a substantial microclot burden, because D-dimer measures active clot breakdown and amyloid fibrin resists that breakdown by definition. This disconnect has caused real confusion for patients who feel certain something is wrong but keep getting normal lab results back.
Where the Field Needs to Go
The gap between what researchers can detect in a well-equipped lab and what a patient can access through their doctor remains wide. Closing that gap requires progress on several fronts simultaneously. Protocols for sample collection, processing, and staining need to be standardized so that a positive result in one lab means the same thing as a positive result in another. Reference ranges need to be established for healthy populations across different ages and backgrounds, since no one has yet defined what a “normal” microclot level looks like with enough statistical power to set clinical thresholds. And prospective clinical trials need to connect microclot test results to treatment outcomes, demonstrating that patients whose microclot levels drop on therapy actually have better recovery than those whose levels stay high.
Automated image analysis and high-throughput methods like imaging flow cytometry bring scalability within reach, and point-of-care optical sensors could eventually make some form of clot profiling accessible in a primary care setting. The science of what microclots are and how to detect them has advanced faster than the clinical infrastructure needed to turn those discoveries into usable diagnostic tools. For patients, the practical takeaway is that microclot testing exists, it measures something real, and it is getting better, but it is not yet at the stage where a result can reliably drive treatment decisions outside of a research context.